FDA Approves Novartis’ New IL-17A-Blocking Psoriasis Drug Cosentyx
Novartis' Cosentyx is the first approved human monoclonal antibody that selectively binds to interleukin IL-17A.
Novartis' Cosentyx is the first approved human monoclonal antibody that selectively binds to interleukin IL-17A.